Dernières nouvelles pour Daiichi Sankyo Co (OTC:DSNKY) Stock

DAIICHI SANKYO

Daiichi Sankyo Co

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

DAIICHI SANKYO S/ADR by Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co Ltd

Press Releases

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

DSNKY

GRAL

TYO:4568

Comments

Daiichi Sankyo Co

Actualités

Dernières nouvelles pour Daiichi Sankyo Co (OTC:DSNKY) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL